Study of Efficacy and Safety of Investigational Treatment in Patients With Nail Psoriasis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
Part 1 is a randomized, double-blind, placebo-controlled phase 1b study to evaluate AT193 in approximately 34 patients with nail psoriasis for 16 weeks. Part 2 is an open-label extension phase where all patients will receive active drug for an additional 16 weeks followed by a 2 week nontreatment period.
Epistemonikos ID: f136ac7d4efd4cdd926880cd0af650de26781004
First added on: May 09, 2024